Released : May 01, 2019 07:00 RNS Number : 6577X MaxCyte, Inc. 01 May 2019 MaxCyte Presents at 22 nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing - CARMA drug candidates can be manufactured via streamlined,
Released : April 24, 2019 07:00 RNS Number : 8683W MaxCyte, Inc. 24 April 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Reports Final Results for Year Ended 31 December 2018 ¾ First CARMA™ cell therapeutic programme targeting treatment of solid tumours has advanced into
Released : April 08, 2019 07:00 RNS Number : 3613V MaxCyte, Inc. 08 April 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte® Launches ExPERT™ Instrument Family to Provide a Unifying Technology Platform from Concept to Commercialization for Next-Generation Cellular Therapies
Released : March 26, 2019 07:00 RNS Number : 9554T MaxCyte, Inc. 26 March 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of Full Year Results Gaithersburg, Maryland - 26 March 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, will be
Released : March 19, 2019 17:05 RNS Number : 3554T MaxCyte, Inc. 19 March 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Director Dealings Issue of Equity Gaithersburg, Maryland - 19 March 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company,
Gaithersburg, Maryland – March 18, 2019: MaxCyte announced today that Debra K. Bowes , Chief Business Officer, CARMA™ Cell Therapy, will present “Novel mRNA-based Autologous CAR Therapies in Oncology” at two upcoming industry conferences. The 13th Annual International Partnering Conference
Released : March 01, 2019 07:00 RNS Number : 5188R MaxCyte, Inc. 01 March 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Announces Multi-Drug Clinical & Commercial Agreement with Kite, a Gilead Company Gaithersburg, Maryland - 01 March 2019: MaxCyte (LSE: MXCT, MXCS),
Released : February 26, 2019 17:32 RNS Number : 1971R MaxCyte, Inc. 26 February 2019 THIS ANNOUNCEMENT IS RESTRICTED AND NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (OR TO ANY US PERSON), CANADA , AUSTRALIA , JAPAN OR
Released : February 05, 2019 16:32 RNS Number : 1641P MaxCyte, Inc. 05 February 2019 THIS ANNOUNCEMENT IS RESTRUCTED AND NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH
Released : March 05, 2019 07:00 RNS Number : 8081R MaxCyte, Inc. 05 March 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Maryland, USA - 05 March 2019 : MaxCyte (LSE: MXCT, MXCS ), the global cell-based medicines and life sciences company , announces that on 04
